Metropolitan Life Insurance Company (MetLife)’s Ultragenyx Pharmaceutical RARE Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,554	Closed	-$299K	–	2593
2021 Q4	$299K	Buy	3,554 +12	+0.3%	+$976	﹤0.01%	1742
2021 Q3	$319K	Sell	3,542 -119	-3%	-$10.8K	﹤0.01%	1730
2021 Q2	$349K	Sell	3,661 -13,329	-78%	-$1.39M	﹤0.01%	1754
2021 Q1	$1.93M	Sell	16,990 -590	-3%	-$80.3K	0.03%	532
2020 Q4	$2.43M	Buy	17,580 +1,059	+6%	+$126K	0.04%	400
2020 Q3	$1.36M	Sell	16,521 -713	-4%	-$59.1K	0.02%	588
2020 Q2	$1.35M	Buy	17,234 +646	+4%	+$42.8K	0.02%	574
2020 Q1	$737K	Sell	16,588 -711	-4%	-$36.9K	0.02%	831
2019 Q4	$739K	Sell	17,299 -399	-2%	-$16.5K	0.01%	1093
2019 Q3	$757K	Buy	17,698 +807	+5%	+$43.8K	0.01%	1026
2019 Q2	$1.07M	Buy	16,891 +238	+1%	+$15.1K	0.02%	854
2019 Q1	$1.16M	Buy	16,653 +1,268	+8%	+$72.4K	0.02%	810
2018 Q4	$669K	Buy	15,385 +198	+1%	+$10.8K	0.01%	1028
2018 Q3	$1.16M	Hold	15,187	–	–	0.02%	854
2018 Q2	$1.17M	Buy	15,187 +1,037	+7%	+$67K	0.02%	844
2018 Q1	$722K	Buy	14,150 +1,481	+12%	+$74.6K	0.01%	1060
2017 Q4	$588K	Sell	12,669 -13,804	-52%	-$677K	0.01%	1175
2017 Q3	$1.41M	Hold	26,473	–	–	0.01%	1075
2017 Q2	$1.64M	Hold	26,473	–	–	0.01%	1015
2017 Q1	$1.79M	Buy	26,473 +1,299	+5%	+$99K	0.01%	985
2016 Q4	$1.77M	Sell	25,174 -425	-2%	-$30.2K	0.01%	1017
2016 Q3	$1.82M	Sell	25,599 -2,148	-8%	-$137K	0.01%	987
2016 Q2	$1.36M	Hold	27,747	–	–	0.01%	1092
2016 Q1	$1.76M	Buy	27,747 +1,243	+5%	+$81.3K	0.01%	936
2015 Q4	$2.97M	Hold	26,504	–	–	0.02%	742
2015 Q3	$2.55M	Buy	26,504 +1,528	+6%	+$175K	0.02%	807
2015 Q2	$2.56M	Buy	+24,976	New	+$1.94M	0.02%	860
2015 Q1	–	Sell	-5,748	Closed	-$252K	–	2389
2014 Q4	$252K	Hold	5,748	–	–	﹤0.01%	2241
2014 Q3	$325K	Sell	5,748 -1,511	-21%	-$76K	﹤0.01%	2018
2014 Q2	$326K	Sell	7,259 -222	-3%	-$9.14K	﹤0.01%	2138
2014 Q1	$366K	Buy	+7,481	New	+$385K	﹤0.01%	2021

Other funds holding RARE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s RARE Position: Q1 2022 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2022, closing a stake of 3,554 shares — an estimated $299K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in RARE in Q1 2014 and held it in 31 quarters. The position peaked at $2.97M in Q4 2015. 240 funds tracked by Wall St. Rank hold RARE as of Q1 2022.

Metropolitan Life Insurance Company (MetLife) reported no remaining Ultragenyx Pharmaceutical position as of Q1 2022 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 3,554 Ultragenyx Pharmaceutical shares in Q1 2022, an estimated $299K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and held it in 31 quarters.
Metropolitan Life Insurance Company (MetLife)'s Ultragenyx Pharmaceutical position peaked at $2.97M in Q4 2015.
240 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2022.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q1 2022, filed 12 May 2022.